Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0201 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0061 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0061 | 0 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0201 | 1 | 0.5 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0201 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.0201 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0 | 0.5 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0201 | 1 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0201 | 1 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0061 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0061 | 0 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0201 | 1 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0061 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0201 | 1 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0061 | 0 | 0.5 |
Brugia malayi | RNA binding protein | 0.0061 | 0 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0061 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.